Brainstorm Cell Therapeutics Inc. (BCLI)

NASDAQ: BCLI · Real-Time Price · USD
1.260
+0.010 (0.80%)
Nov 20, 2024, 4:00 PM EST - Market closed
0.80%
Market Cap 6.70M
Revenue (ttm) n/a
Net Income (ttm) -14.23M
Shares Out 5.32M
EPS (ttm) -3.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 40,356
Open 1.250
Previous Close 1.250
Day's Range 1.250 - 1.300
52-Week Range 1.050 - 11.850
Beta 0.39
Analysts Strong Buy
Price Target 30.00 (+2,280.95%)
Earnings Date Nov 14, 2024

About BCLI

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing Nu... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 29
Stock Exchange NASDAQ
Ticker Symbol BCLI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for BCLI stock is "Strong Buy" and the 12-month stock price forecast is $30.0.

Price Target
$30.0
(2,280.95% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Conference call planned for later in Q4 2024 to provide updates on NurOwn® program NEW YORK , Nov. 14, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adu...

6 days ago - PRNewsWire

BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing

Memorandum of Understanding has been signed NEW YORK , Nov. 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative d...

Other symbols: PLUR
9 days ago - PRNewsWire

BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

NEW YORK , Oct. 30, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that on October 29,...

21 days ago - PRNewsWire

BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS Meeting

Biomarker data suggest ALS patients may benefit from longer-term treatment with NurOwn Poster highlighting design of planned Phase 3b NurOwn trial also presented NEW YORK , Oct. 28, 2024 /PRNewswire/ ...

23 days ago - PRNewsWire

BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual Summit

NEW YORK , Oct. 7, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced its partici...

6 weeks ago - PRNewsWire

BrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS Meeting

NEW YORK , Sept. 24, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the acceptance of ...

2 months ago - PRNewsWire

Brainstorm Cell Therapeutics Inc. (BCLI) Q2 2024 Earnings Call Transcript

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Michael Wood - LifeSci Advisors Chaim Lebovits - President and CEO All...

3 months ago - Seeking Alpha

BrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

- Company reached alignment with the U.S. FDA on the Chemistry, Manufacturing, and Controls (CMC) aspects of its planned Phase 3b clinical trial for NurOwn® in ALS - SPA in place for Phase 3b NurOwn® ...

3 months ago - PRNewsWire

BrainStorm Cell Therapeutics to Announce Second Quarter Results and Provide a Corporate Update

NEW YORK , Aug. 7, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it wi...

3 months ago - PRNewsWire

BCLI Update - Progress Supports Our 10x Plus Value Range Potential

ACF Equity Research  FROM ACF EQUITY RESEARCH HEALTHCARE TEAM LONDON , July 24, 2024 /PRNewswire/ --  NASDAQ: BCLI READ ACF EQUITY RESEARCH'S UPDATE NOTE HERE  READ ACF EQUITY RESEARCH'S RELATED THEMA...

4 months ago - PRNewsWire

Brainstorm Cell Therapeutics Inc. (BCLI) Corporate Mid-Year Update on NurOwn Program (Transcript)

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Corporate Mid-Year Update on NurOwn Program July 8, 2024 8:00 AM ET Company Participants Joyce Lonergan - LifeSci Advisors Chaim Lebovits - President a...

4 months ago - Seeking Alpha

BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program

A conference call and webcast will be held Monday, July 8, at 8:00 a.m. Eastern Time NEW YORK , July 1, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of ad...

5 months ago - PRNewsWire

BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering

NEW YORK , June 27, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) (the "Company"), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today ann...

5 months ago - PRNewsWire

BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial

NEW YORK , June 26, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced it has re...

5 months ago - PRNewsWire

BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer

Appointment Completes Executive Readiness for Registrational Phase 3b ALS Study Launch NEW YORK , June 20, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of...

5 months ago - PRNewsWire

BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation

FROM ACF EQUITY RESEARCH HEALTHCARE TEAM NASDAQ: BCLI READ ACF EQUITY RESEARCH'S INITIATION NOTE HERE  READ ACF EQUITY RESEARCH'S RELATED THEMATIC RESEARCH NOTE ON REGENERATIVE MEDICINE – NEURODEGENER...

5 months ago - PRNewsWire

BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn

The data will be presented at the Annual ALS Drug Development Summit, which is focused on identifying transformative ALS targets, seeking translational biomarkers and propelling more clinical approval...

6 months ago - PRNewsWire

BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Company received written agreement from the U.S. FDA under a Special Protocol Assessment (SPA) on the design for a Phase 3b trial of NurOwn® Conference call planned for later this quarter to provide u...

6 months ago - PRNewsWire

BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn

Bob Dagher, MD, Promoted to Chief Medical Officer Dr. Stacy Lindborg Stepping Down as Co-CEO and Transitioning to Board of Directors   NEW YORK , April 16, 2024 /PRNewswire/ -- BrainStorm Cell Therape...

7 months ago - PRNewsWire

BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule

NEW YORK , April 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI, "the Company"), a leading developer of cellular therapies for neurodegenerative diseases, today announced tha...

7 months ago - PRNewsWire

BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS

NurOwn treatment resulted in a positive impact on important CSF biomarkers relevant to ALS compared to placebo.Significant changes in multiple ALS disease pathways support NurOwn's mechanism of action...

8 months ago - PRNewsWire

BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS

Conference call and webcast at 8:00 a.m. Eastern Time today NEW YORK , April 9, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeuti...

8 months ago - PRNewsWire

BrainStorm Cell Therapeutics to Provide Update on NurOwn Program

A conference call and webcast will be held Tomorrow, April 9, at 8:00 a.m. Eastern Time NEW YORK , April 8, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer o...

8 months ago - PRNewsWire

BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update

Conference call planned for early April 2024 to provide update on NurOwn program NEW YORK , April 1, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult...

8 months ago - PRNewsWire

BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference

Planned Phase 3b trial Designed to Confirm Efficacy and Safety  of NurOwn in mild-to-moderate ALS patients NEW YORK , Feb. 27, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a ...

9 months ago - PRNewsWire